StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

Alnylam Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Alnylam Pharmaceuticals's pe ratio was 28.1× on Nov 11, 2026, against 564.0× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202628.1×−468.9
2025Dec 31, 2025497.1×–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?